insights_auto
Pse është ulur FARN 3,92%?
Zhytu më thellëchevron_right
FARN:LON
Faron Pharmaceuticals Oy
35,07Â GBX
arrow_downward
-3,92%(-1,43) 1D
13 tet, 12:38:21 m.d., GMT+1 · GBX
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për FARN...
Hap
38,00Â GBX
I lartë
38,00Â GBX
I ulët
35,07Â GBX
Kapitalizimi i tregut
71,06Â mln
Vëllimi mesatar
42,86 mijë
Vëllimi
26,30 mijë
Maksimumi 52-javor
193,58Â GBX
Minimumi 52-javor
34,00Â GBX
Fitimet për aksion
-0,10Â GBX
Aksionet në qarkullim
31,03Â mln
Numri i punonjësve
36
Hap
38,00Â GBX
I lartë
38,00Â GBX
I ulët
35,07Â GBX
Kapitalizimi i tregut
71,06Â mln
Vëllimi mesatar
42,86 mijë
Vëllimi
26,30 mijë
Maksimumi 52-javor
193,58Â GBX
Minimumi 52-javor
34,00Â GBX
Fitimet për aksion
-0,10Â GBX
Aksionet në qarkullim
31,03Â mln
Numri i punonjësve
36
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
GlobeNewswire
·
14 minuta më parë
Primech Holdings (Nasdaq: PMEC) to Present at LD Micro Main
Business Wire
·
29 minuta më parë
Powerus (Nasdaq: PUSA) Unveils Fully Autonomous Drone Interceptors at AUSA 2026
Stock Titan
·
18 minuta më parë
$1 bid-price compliance regained, but NeuroSense (Nasdaq: NRSN) still faces a listing deficiency.
Profili
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Rreth Faron Pharmaceuticals Oy